Shattuck Labs to participate in a panel discussing insights from the UEGW Conference 2025 on immunology treatments.
Quiver AI Summary
Shattuck Labs, Inc. announced its participation in a panel discussion on key insights from the United European Gastroenterology Week (UEGW) Conference 2025, which will feature Shattuck's CEO, Dr. Taylor Schreiber, alongside notable analysts and a key opinion leader, Dr. Marla Dubinsky. The event is scheduled for October 8, 2025. Shattuck is advancing its lead therapeutic candidate, SL-325, a first-in-class antibody designed to target the DR3/TL1A pathway, which shows promise in treating inflammatory bowel disease and other immune-related conditions. SL-325 is currently undergoing a Phase 1 clinical trial and aims to provide enhanced efficacy and lower immunogenicity compared to existing therapies.
Potential Positives
- Shattuck Labs is participating in a panel discussion at the prestigious United European Gastroenterology Week Conference 2025, highlighting its active engagement in the scientific community.
- The company’s lead program, SL-325, is a potentially first-in-class antibody targeting the DR3/TL1A pathway, suggesting innovative advancements in the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions.
- Preclinical studies of SL-325 show high efficacy and lower immunogenicity compared to existing TL1A blocking antibodies, which could position Shattuck favorably in a competitive market.
- The announcement highlights the leadership and expertise of Shattuck’s CEO, Taylor Schreiber, participating in discussions with key opinion leaders, enhancing the company's reputation in the biotech field.
Potential Negatives
- Participation in a panel discussion may indicate a lack of significant announcements or developments from Shattuck Labs, potentially suggesting limited progress in their therapeutic developments.
- The reliance on a panel discussion for visibility might be seen as insufficient for a company seeking to elevate its profile in a competitive biotechnology landscape.
- Details regarding the Phase 1 clinical trial of SL-325 were not disclosed, leaving stakeholders without critical information on trial progress or projected timelines, which may raise concerns about transparency and investor confidence.
FAQ
What is the focus of Shattuck Labs, Inc.?
Shattuck Labs specializes in developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for inflammatory and immune-related diseases.
When is the panel discussion at UEGW 2025?
The panel discussion is scheduled for October 8, 2025, from 10:00 AM to 12:00 PM EST.
Who will moderate the UEGW 2025 panel discussion?
The session will be moderated by Martin Fan, Ph.D. and David Nierengarten, Ph.D.
What is SL-325?
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at treating inflammatory bowel disease and other conditions.
Where can I find more information about Shattuck Labs?
More information can be found on Shattuck Labs' official website at www.ShattuckLabs.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STTK Insider Trading Activity
$STTK insiders have traded $STTK stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STTK stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED has made 2 purchases buying 6,306,127 shares for an estimated $5,471,826 and 0 sales.
- MONA ASHIYA has made 2 purchases buying 6,306,127 shares for an estimated $5,471,826 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STTK Hedge Fund Activity
We have seen 30 institutional investors add shares of $STTK stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,722,249 shares (-66.1%) from their portfolio in Q2 2025, for an estimated $1,363,676
- STATE STREET CORP removed 606,712 shares (-77.4%) from their portfolio in Q2 2025, for an estimated $480,394
- MILLENNIUM MANAGEMENT LLC added 540,658 shares (+178.7%) to their portfolio in Q2 2025, for an estimated $428,093
- GEODE CAPITAL MANAGEMENT, LLC removed 465,460 shares (-49.9%) from their portfolio in Q2 2025, for an estimated $368,551
- JANE STREET GROUP, LLC added 278,576 shares (+2510.8%) to their portfolio in Q2 2025, for an estimated $220,576
- VANGUARD GROUP INC removed 252,364 shares (-10.5%) from their portfolio in Q2 2025, for an estimated $199,821
- NORTHERN TRUST CORP removed 236,159 shares (-68.0%) from their portfolio in Q2 2025, for an estimated $186,990
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$STTK Analyst Ratings
Wall Street analysts have issued reports on $STTK in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 09/08/2025
- Leerink Partners issued a "Outperform" rating on 08/14/2025
To track analyst ratings and price targets for $STTK, check out Quiver Quantitative's $STTK forecast page.
$STTK Price Targets
Multiple analysts have issued price targets for $STTK recently. We have seen 2 analysts offer price targets for $STTK in the last 6 months, with a median target of $3.0.
Here are some recent targets:
- David Nierengarten from Wedbush set a target price of $4.0 on 09/08/2025
- Faisal Khurshid from Leerink Partners set a target price of $2.0 on 08/14/2025
Full Release
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be moderated by covering analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., and will feature KOL Marla Dubinsky, M.D., Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai Health System.
Conference Details
Format:
Panel Discussion
Session Title:
Wedbush UEGW Conference 2025 Rewind
Moderators:
Martin Fan, Ph.D. and David Nierengarten, Ph.D.
Shattuck Participant:
Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date:
October 8, 2025
Time:
10:00am - 12:00pm EST
Website Link
:
Here
About SL-325
SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies and offer the potential for higher efficacy and lower immunogenicity in comparison to TL1A blocking antibodies. SL-325 is currently being studied in a Phase 1 clinical trial.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. Shattuck is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit:
www.ShattuckLabs.com
.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
[email protected]
